Disruptive Drug Development


Next Generation Organ on Chip Technology

Tissue Dynamics is a Jerusalem-based biotechnology company that aims to disrupt drug development processes, reducing R&D costs by 30% to 80% by providing groundbreaking drug toxicity and efficacy tools for the pharmaceutical industry.

Tissue Dynamics proprietary high screening platform 

utilising tissue-embedded microsensors in a micro-physiological environment to monitor changes in tissue function in real time. Real time data acquisition provides insight into mechanism of action without a priori information, highlighting idiosyncratic toxicity risk and novels drug reformulation strategies. 



DynamIX is a our microfluidic chip supporting 3D human organoids in a human micro-physiological environment



"Animal testing alternative breakthrough... a liver-on-chip device mimicking human physiology "                                             Horizon 2020, Aug. 15, 2015

"Acetaminophen toxic at lower levels than thought" 

UPI, Aug. 17, 2015

"Liver-simulating device surpasses animal-based alternatives" 

European Commission, Oct. 30, 2015

"Novel technology allows assessment of drug induced mitochondrial damage" 

GEN News Highlights, Apr. 5, 2016

"Microchip offers insight into dynamics of cellular function" 

Jerusalem Post, May. 28, 2016

"Scientists invent bionic micro-livers to replace animal testing" 

Haaretz, Nov. 2, 2016


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 827858



We’re happy to hear from you. Contact us today to learn more about our business and how you can benefit from working with us.

  • Facebook Social Icon
  • LinkedIn Social Icon

Your details were sent successfully!